UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

 UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

UCB Reports Improved Results of Extended P-IIb BE ACTIVE study for Bimekizumab in Patients with Psoriatic Arthritis (PsA) Patients

Shots:

  • The P-IIb study involves assessing of bimekizumab (160/320 mg@ 48 wks./16mg @12wks., q4w SC IV) vs PBO in 206 patients in ratio (1:1) with PsA
  • P-IIb BE ACTIVE study results: @12wks. ACR20/50/70/ (20%, 50% vs 7%,70%): PASI90/95 (90%,75%); @ 48wks. ACR20/50/70 (160, loading dose 160, 320): (70%, 73%, 76%; 55%, 57%, 63%; 43%, 46%, 39%); PASI90 (70%, 85%); MDA @12/24/48 wks. ((29-46%), (37-60%), (46-60%))
  • Bimekizumab is a novel mIgG1 Ab neutralizes IL-17A and IL-17F. The above mentioned results are presented at ACR/ARHP18

Click here to read full press release/ article | Ref: UCB | Image: Eatris

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post